Rituximab Clinical Trials

A listing of Rituximab medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

However; the prolonged use of high dose steroids carries significant side effects. A recent randomized trial has proved the efficacy of Rituximab, a monoclonal anti-CD20 antibody against B-lymphocytes, as an efficacious therapy for pemphigus. Early use of rituximab was associated with better clinical outcomes, hence combination treatment of rituximab and …

pemphigus
immunosuppressants
immunosuppressive agents
immunomodulators
corticosteroids
  • 0 views
  • 16 Feb, 2024
  • 1 location
Acalabrutinib Lenalidomide and Rituximab for the Treatment of CD20 Positive Stage III-IV Grade 1-3a Follicular Lymphoma

Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow …

cervical cap
ct scan
lymphoma
human chorionic gonadotropin
beta human chorionic gonadotropin
  • 0 views
  • 16 Feb, 2024
  • 1 location
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

marginal zone lymphoma
rituximab
bortezomib
lymphoma
prednisone
  • 0 views
  • 05 Aug, 2020
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

leukemia
lymphoma
treatment regimen
refractory b-cell non-hodgkin lymphoma
immunochemotherapy
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

The prognosis of DLBCL with MYC rearrangement is dismal. Previous study showed that lenalidomide in combination with R-CHOP showed promising therapeutic activity and that R-DA EPOCH was superior compared to R-CHOP regimen in this cohort of patients. The investigators therefore design this phase I/II study to investigate the safety and …

r-chop regimen
r-da-epoch
lymphoma
etoposide
prednisone
  • 0 views
  • 16 Feb, 2024
  • 1 location
Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Describe the treatment of B-cell non-Hodgkin lymphoma patients who receive lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs), and evaluate the efficacy and safety of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs) in the real-world setting.

rituximab
hodgkin's disease
b-cell lymphoma
lymphoma
lenalidomide
  • 0 views
  • 16 Feb, 2024
  • 1 location